NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $163,270 | -69.3% | 232,280 | -1.2% | 0.00% | -100.0% |
| Q4 2022 | $531,511 | -28.7% | 235,182 | +1.0% | 0.00% | 0.0% |
| Q3 2022 | $745,000 | -17.2% | 232,749 | -1.8% | 0.00% | 0.0% |
| Q2 2022 | $900,000 | -29.0% | 236,904 | +0.7% | 0.00% | -50.0% |
| Q1 2022 | $1,268,000 | -63.0% | 235,229 | -7.3% | 0.00% | -50.0% |
| Q4 2021 | $3,428,000 | -36.7% | 253,774 | -15.9% | 0.00% | -42.9% |
| Q3 2021 | $5,418,000 | +4.5% | 301,694 | -0.1% | 0.01% | 0.0% |
| Q2 2021 | $5,185,000 | -13.9% | 302,128 | +0.4% | 0.01% | -12.5% |
| Q1 2021 | $6,021,000 | +17.2% | 301,061 | -0.3% | 0.01% | +14.3% |
| Q4 2020 | $5,136,000 | +4.1% | 302,095 | +1.6% | 0.01% | -12.5% |
| Q3 2020 | $4,933,000 | -26.9% | 297,328 | +2.0% | 0.01% | -33.3% |
| Q2 2020 | $6,750,000 | +34.9% | 291,458 | +4.0% | 0.01% | +9.1% |
| Q1 2020 | $5,004,000 | -12.5% | 280,358 | +5.9% | 0.01% | +10.0% |
| Q4 2019 | $5,716,000 | +11.8% | 264,798 | -5.7% | 0.01% | 0.0% |
| Q3 2019 | $5,114,000 | -48.2% | 280,733 | +1.2% | 0.01% | -47.4% |
| Q2 2019 | $9,872,000 | +13.9% | 277,459 | +7.6% | 0.02% | +5.6% |
| Q1 2019 | $8,665,000 | +2.7% | 257,880 | +0.5% | 0.02% | -5.3% |
| Q4 2018 | $8,435,000 | -44.6% | 256,624 | +2.8% | 0.02% | -36.7% |
| Q3 2018 | $15,224,000 | +24.8% | 249,745 | +0.0% | 0.03% | +20.0% |
| Q2 2018 | $12,194,000 | -49.9% | 249,715 | +9.0% | 0.02% | -51.9% |
| Q1 2018 | $24,348,000 | +74.3% | 229,137 | -2.1% | 0.05% | +79.3% |
| Q4 2017 | $13,972,000 | +145.3% | 233,964 | -1.4% | 0.03% | +123.1% |
| Q3 2017 | $5,696,000 | +10.9% | 237,344 | -9.6% | 0.01% | +18.2% |
| Q2 2017 | $5,134,000 | -21.9% | 262,620 | -6.3% | 0.01% | -15.4% |
| Q1 2017 | $6,577,000 | +82.6% | 280,242 | -4.5% | 0.01% | +85.7% |
| Q4 2016 | $3,601,000 | -23.6% | 293,442 | +7.0% | 0.01% | -30.0% |
| Q3 2016 | $4,711,000 | +21.7% | 274,242 | +0.8% | 0.01% | +25.0% |
| Q2 2016 | $3,870,000 | +0.7% | 271,942 | -2.7% | 0.01% | 0.0% |
| Q1 2016 | $3,842,000 | -6.5% | 279,426 | +14.6% | 0.01% | -20.0% |
| Q4 2015 | $4,108,000 | +56.3% | 243,779 | +1.7% | 0.01% | +42.9% |
| Q3 2015 | $2,628,000 | -12.5% | 239,815 | -0.2% | 0.01% | 0.0% |
| Q2 2015 | $3,005,000 | +17.5% | 240,215 | +3.3% | 0.01% | +16.7% |
| Q1 2015 | $2,558,000 | -45.7% | 232,542 | -23.6% | 0.01% | -45.5% |
| Q4 2014 | $4,715,000 | +66.7% | 304,202 | +29.8% | 0.01% | +57.1% |
| Q3 2014 | $2,828,000 | -4.8% | 234,340 | +1.1% | 0.01% | 0.0% |
| Q2 2014 | $2,972,000 | +7.9% | 231,809 | +2.0% | 0.01% | 0.0% |
| Q1 2014 | $2,754,000 | +16.1% | 227,209 | +8.7% | 0.01% | +16.7% |
| Q4 2013 | $2,372,000 | +9.3% | 209,009 | +0.6% | 0.01% | 0.0% |
| Q3 2013 | $2,171,000 | -6.6% | 207,709 | +3.2% | 0.01% | -25.0% |
| Q2 2013 | $2,325,000 | +6.1% | 201,261 | +1.0% | 0.01% | +14.3% |
| Q1 2013 | $2,192,000 | – | 199,294 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |